Piper Sandler Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $36.00

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective trimmed by Piper Sandler from $37.00 to $36.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the specialty pharmaceutical company’s stock.

COLL has been the subject of several other research reports. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Trading Up 0.8 %

Shares of Collegium Pharmaceutical stock opened at $30.95 on Tuesday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $998.14 million, a PE ratio of 13.34 and a beta of 0.82. Collegium Pharmaceutical has a 1-year low of $28.39 and a 1-year high of $42.29. The company’s fifty day simple moving average is $31.03 and its 200-day simple moving average is $34.14.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in COLL. Nisa Investment Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. Foundry Partners LLC boosted its holdings in shares of Collegium Pharmaceutical by 3.3% during the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the last quarter. Caprock Group LLC grew its position in shares of Collegium Pharmaceutical by 6.7% during the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after purchasing an additional 543 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after purchasing an additional 642 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.